Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients.

Remon J, Steuer CE, Ramalingam SS, Felip E.

Ann Oncol. 2018 Jan 1;29(suppl_1):i20-i27. doi: 10.1093/annonc/mdx704.

PMID:
29462255
2.

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.

Santarpia M, Liguori A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, D'Aveni A, Marabello G, Altavilla G, Rosell R.

Lung Cancer (Auckl). 2017 Aug 18;8:109-125. doi: 10.2147/LCTT.S119644. eCollection 2017. Review.

3.

A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.

Jiang T, Su C, Ren S, Cappuzzo F, Rocco G, Palmer JD, van Zandwijk N, Blackhall F, Le X, Pennell NA, Zhou C; written on behalf of the AME Lung Cancer Collaborative Group.

J Thorac Dis. 2018 Jul;10(7):3909-3921. doi: 10.21037/jtd.2018.07.61. Review.

4.
5.

Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.

Tan CS, Cho BC, Soo RA.

Lung Cancer. 2016 Mar;93:59-68. doi: 10.1016/j.lungcan.2016.01.003. Epub 2016 Jan 8. Review.

PMID:
26898616
6.

Treating EGFR mutation resistance in non-small cell lung cancer - role of osimertinib.

Mazza V, Cappuzzo F.

Appl Clin Genet. 2017 Jul 26;10:49-56. doi: 10.2147/TACG.S103471. eCollection 2017. Review.

7.

Overcoming T790M mutant small cell lung cancer with the third-generation EGFR-TKI osimertinib.

Tang K, Jiang N, Kuang Y, He Q, Li S, Luo J, Jiang W, Chen Y, Sun Y, Chen L, Chen Y, Zhu J, Cui Y, Wan H, Ke Z.

Thorac Cancer. 2019 Feb;10(2):359-364. doi: 10.1111/1759-7714.12927. Epub 2018 Dec 6.

8.

Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR.

Sakai H, Hayashi H, Iwasa T, Hasegawa Y, Takeda M, Nakagawa K.

ESMO Open. 2017 Mar 7;2(Suppl 1):e000104. doi: 10.1136/esmoopen-2016-000104. eCollection 2017.

9.

Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.

Liao BC, Lin CC, Lee JH, Yang JC.

Lung Cancer. 2017 Aug;110:7-13. doi: 10.1016/j.lungcan.2017.05.009. Epub 2017 May 11. Review.

PMID:
28676222
10.

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.

La Monica S, Minari R, Cretella D, Flammini L, Fumarola C, Bonelli M, Cavazzoni A, Digiacomo G, Galetti M, Madeddu D, Falco A, Lagrasta CA, Squadrilli A, Barocelli E, Romanel A, Quaini F, Petronini PG, Tiseo M, Alfieri R.

J Exp Clin Cancer Res. 2019 May 28;38(1):222. doi: 10.1186/s13046-019-1240-x.

11.

Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example.

Wei B, Zhao C, Li J, Zhao J, Ren P, Yang K, Yan C, Sun R, Ma J, Guo Y.

Mol Oncol. 2019 May;13(5):1226-1234. doi: 10.1002/1878-0261.12481. Epub 2019 Apr 10.

12.

Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line.

Sullivan I, Planchard D.

Front Med (Lausanne). 2017 Jan 18;3:76. doi: 10.3389/fmed.2016.00076. eCollection 2016. Review.

13.
14.

Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).

Saad N, Poudel A, Basnet A, Gajra A.

Onco Targets Ther. 2017 Mar 22;10:1757-1766. doi: 10.2147/OTT.S100650. eCollection 2017. Review.

15.

Integrating Osimertinib in Clinical Practice for Non-Small Cell Lung Cancer Treatment.

Rajappa S, Krishna MV, Narayanan P.

Adv Ther. 2019 Jun;36(6):1279-1290. doi: 10.1007/s12325-019-00917-6. Epub 2019 Apr 2. Review.

PMID:
30941723
16.

EGFR L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib.

Ma L, Chen R, Wang F, Ma LL, Yuan MM, Chen RR, Liu J.

Ann Transl Med. 2019 May;7(9):207. doi: 10.21037/atm.2019.04.37.

17.

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy.

Ricciuti B, Baglivo S, Paglialunga L, De Giglio A, Bellezza G, Chiari R, Crinò L, Metro G.

Ther Adv Med Oncol. 2017 Jun;9(6):387-404. doi: 10.1177/1758834017702820. Epub 2017 Apr 16. Review.

18.

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.

Hochmair MJ, Buder A, Schwab S, Burghuber OC, Prosch H, Hilbe W, Cseh A, Fritz R, Filipits M.

Target Oncol. 2019 Feb;14(1):75-83. doi: 10.1007/s11523-018-0612-z.

19.

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines.

La Monica S, Cretella D, Bonelli M, Fumarola C, Cavazzoni A, Digiacomo G, Flammini L, Barocelli E, Minari R, Naldi N, Petronini PG, Tiseo M, Alfieri R.

J Exp Clin Cancer Res. 2017 Dec 4;36(1):174. doi: 10.1186/s13046-017-0653-7.

20.

Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer.

Ichihara E, Hotta K, Ninomiya K, Kubo T, Ohashi K, Rai K, Tanaka H, Tabata M, Maeda Y, Kiura K.

Lung Cancer. 2019 Jun;132:54-58. doi: 10.1016/j.lungcan.2019.02.021. Epub 2019 Apr 6.

PMID:
31097094

Supplemental Content

Support Center